Emerging data suggest Retatru tide , a dual stimulator targeting both incretin and GIP , could offer a promising development for obesity management . Initial patient trials have demonstrated https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide